Journal article

RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

Man-Fung Yuen, Ingolf Schiefke, Jung-Hwan Yoon, Sang Hoon Ahn, Jeong Heo, Ju Hyun Kim, Henry Lik Yuen Chan, Ki Tae Yoon, Hartwig Klinker, Michael Manns, Joerg Petersen, Thomas Schluep, James Hamilton, Bruce D Given, Carlo Ferrari, Ching-Lung Lai, Stephen A Locarnini, Robert G Gish

Hepatology | WILEY | Published : 2020

Abstract

BACKGROUND AND AIMS: ARC-520, the first an RNA interference (RNAi) therapeutic, was designed to reduce all RNA transcripts derived from covalently closed circular DNA, leading to a reduction in viral antigens and hepatitis B virus (HBV) DNA. APPROACH AND RESULTS: We aimed to evaluate the depth of hepatitis B surface antigen (HBsAg) decline in response to multiple doses of ARC-520 compared to placebo (PBO) in two randomized, multicenter studies in nucleoside/nucleotide analogue reverse-transcriptase inhibitor (NUC)-experienced patients with hepatitis B early antigen (HBeAg)-negative (E-neg) or HBeAg-positive (E-pos) disease. A total of 58 E-neg and 32 E-pos patients were enrolled and received..

View full abstract

Grants

Funding Acknowledgements

Supported by Arrowhead Pharmaceuticals, Inc.